



Extraordinary General Meeting held on March 31, 2025 iV Poll Results

Hong Kong, Shanghai, & Florham Park, NJ: Monday, March 31, 2025: HUTCHMED (China) Limited (i§HUTCHMEDi or the i§Companyi) (Nasdaq/AIM: HCM; HKEX:13) today announces that the ordinary resolution put to its Extraordinary General Meeting (i§EGMi) held on March 31, 2025 was duly passed.

Reference is made to the notice of EGM dated March 14, 2025 and the circular to shareholders dated March 14, 2025 (the i§Circulari) issued by the Company. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The poll results of the ordinary resolution were as follows:

Ordinary Resolution	Number of Votes (%)*			Passed by Shareholders
	For	Against	Withheld#	
To approve the transactions related to the sale and purchase of a total of 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited under various agreements, and all actions by the Company and/or its subsidiaries pursuant or incidental to such transactions.	475,229,253 (99.9745%)	121,270 (0.0255%)	1,670	Yes

* Percentages rounded to 4 decimal places.

A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a resolution.

The full text of the resolution is set out in the notice of EGM dated March 14, 2025.

Notes:

- (1) Except for Ms Ling YANG who had prior overseas commitments and was unable to attend the EGM, all directors of the Company, namely Dr Dan ELDAR, Dr Weiguo SU, Mr CHENG Chig Fung, Johnny, Ms Edith SHIH, Mr Paul Rutherford CARTER, Dr Renu BHATIA, Dr Chaohong HU, Mr Graeme Allan JACK, Professor MOK Shu Kam, Tony and Mr WONG Tak Wai, attended the EGM, either in person or by means of electronic facilities.
- (2) Number of shares entitling the holders to attend and vote on the resolution at the EGM: 871,601,095 shares.
- (3) Number of shares entitling the holders to attend and abstain from voting in favor as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the i§Listing Rulesi) at the EGM: Nil.
- (4) Number of shares for holders required under the Listing Rules to abstain from voting at the EGM: Nil.
- (5) The scrutineer for the poll at the EGM was Computershare Investor Services (Jersey) Limited, the Principal Share Registrar of the Company.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, and the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch.med.com or follow us on [LinkedIn](#).

CONTACTS

Investor Enquiries+852 2121 8200 / ir@hutch-med.com**Media Enquiries**

FTI Consulting JV

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

Ben Atwell / Alex Shaw

+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)

Brunswick JV Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com**Panmure Liberum***Nominated Advisor and Joint Broker*

Atholl Tweedie / Freddy Crossley / Rupert Dearden

+44 20 7886 2500

HSBC*Joint Broker*

Simon Alexander / Alina Vaskina / Arnav Kapoor

+44 20 7991 8888

Cavendish*Joint Broker*

Geoff Nash / Nigel Birks

+44 20 7220 0500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMPKDBQFBKKPNN